FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080285165> ?p ?o ?g. }

• W2080285165 endingPage "22614" @default.
• W2080285165 startingPage "22609" @default.
• W2080285165 abstract "Protein tyrosine phosphatase (PTP)-MEG2 is an intracellular tyrosine phosphatase that contains a Sec14 homology domain. We have purified the full-length and truncated forms of the enzyme from recombinant adenovirus-infected human 293 cells. By using lipid-membrane overlay and liposome binding assays, we demonstrated that PTP-MEG2 specifically binds phosphatidylserine among over 20 lipid compounds tested. The binding is mediated by its N-terminal Sec14 domain. In intact cells, the Sec14 domain is responsible for localization of PTP-MEG2 to the perinuclear region, and uploading of PS into the cell membrane causes translocation of PTP-MEG2 to the plasma membrane. Phosphatidylserine is a relatively abundant cell membrane phospholipid non-symmetrically distributed in the outer layer and inner layer of cell membranes. It has recently been defined as an important ligand for clearance of apoptotic cells. By specifically binding phosphatidylserine, PTP-MEG2 may play an important role in regulating signaling processes associated with phagocytosis of apoptotic cells. Protein tyrosine phosphatase (PTP)-MEG2 is an intracellular tyrosine phosphatase that contains a Sec14 homology domain. We have purified the full-length and truncated forms of the enzyme from recombinant adenovirus-infected human 293 cells. By using lipid-membrane overlay and liposome binding assays, we demonstrated that PTP-MEG2 specifically binds phosphatidylserine among over 20 lipid compounds tested. The binding is mediated by its N-terminal Sec14 domain. In intact cells, the Sec14 domain is responsible for localization of PTP-MEG2 to the perinuclear region, and uploading of PS into the cell membrane causes translocation of PTP-MEG2 to the plasma membrane. Phosphatidylserine is a relatively abundant cell membrane phospholipid non-symmetrically distributed in the outer layer and inner layer of cell membranes. It has recently been defined as an important ligand for clearance of apoptotic cells. By specifically binding phosphatidylserine, PTP-MEG2 may play an important role in regulating signaling processes associated with phagocytosis of apoptotic cells. Protein tyrosine phosphatases (PTPs) 1The abbreviations used are: PTP, protein tyrosine phosphatase; PS, phosphatidylserine; PSR, PS receptor; PC, phosphatidylcholine; PE, phosphatidylethanolamine; pNPP, para-nitrophenyl phosphate; BSA, bovine serum albumin. 1The abbreviations used are: PTP, protein tyrosine phosphatase; PS, phosphatidylserine; PSR, PS receptor; PC, phosphatidylcholine; PE, phosphatidylethanolamine; pNPP, para-nitrophenyl phosphate; BSA, bovine serum albumin. consist of a highly diverse family of enzyme with crucial roles in cell signaling (1Fischer E.H. Charbonneau H. Tonks N.K. Science. 1991; 253: 401-406Crossref PubMed Scopus (863) Google Scholar, 2Walton K.M. Dixon J.E. Annu. Rev. Biochem. 1993; 62: 101-120Crossref PubMed Scopus (414) Google Scholar, 3Tonks N.K. Neel B.G. Curr. Opin. Cell Biol. 2001; 13: 182-195Crossref PubMed Scopus (462) Google Scholar). Like their counterpart protein tyrosine kinases, PTPs can be divided into transmembrane receptor-like and intracellular enzymes. The intracellular PTPs contain a single conserved phosphatase domain. Beyond the limit of the catalytic domains are various segments or domains that modulate the activity and/or intracellular localization of the enzymes. Among these is the Sec14 domain found in PTP-MEG2 (4Gu M. Warshawsky I. Majerus P.W. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 2980-2984Crossref PubMed Scopus (78) Google Scholar). The Sec14 domain is shared by several lipid-binding proteins such as cellular retinaldehyde-binding protein (CRALBP), α-tocopherol transfer protein, and yeast Sec14p and by regulators of G proteins including RhoGAPs, RhoGEFs and the RasGEF, and neurofibromin (5Aravind L. Neuwals A.F. Ponting C.P. Curr. Biol. 1999; 9: R195-R197Abstract Full Text Full Text PDF PubMed Google Scholar). CRALBP is a water-soluble protein found in the retina and pineal gland. It acts as a carrier protein for 11-cis-retinaldehyde or 11-cis-retinol and modulates the interactions of these retinoids with visual cycle enzymes (6Wolf G. Nutr. Rev. 1991; 49: 1-12Crossref PubMed Scopus (42) Google Scholar). α-Tocopherol transfer protein specifically sorts out α-tocopherol from all incoming tocopherols for incorporation into plasma lipoproteins (7Sato Y. Arai H. Miyata A. Tokita S. Yamamoto K. Tanabe T. Inoue K. J. Biol. Chem. 1993; 268: 17705-17710Abstract Full Text PDF PubMed Google Scholar). Sec14p acts as a phosphatidylinositol transfer protein by catalyzing the transfer of phosphatidylinositol and phosphatidylcholine between membrane bilayers, and it is required for protein transport through the Golgi complex in Saccharomyces cerevisiae (8Aitken J.F. van Heusden G.P. Temkin M. Dowhan W. J. Biol. Chem. 1990; 265: 4711-4717Abstract Full Text PDF PubMed Google Scholar, 9Bankaitis V.A. Aitken J.R. Cleves A.E. Dowhan W. Nature. 1990; 347: 561-562Crossref PubMed Scopus (434) Google Scholar). With significant sequence homology to these lipid-binding proteins, PTP-MEG2 may also bind certain lipid molecules that may regulate its activity and/or localization. A ligand for the Sec14 domain of PTP-MEG2 has not been found. In this study, we examined the interaction of PTP-MEG2 with various known lipid molecules and demonstrated that phosphatidylserine (PS) specifically interacts with PTP-MEG2. PS is a relatively abundant membrane lipid molecule. Recently, it has been defined as an important ligand for clearance of apoptotic cells through the PS receptor (PSR) located on the surface of phagocytes (10Schlegel R.A. Williamson P. Cell Death Differ. 2001; 8: 551-563Crossref PubMed Scopus (291) Google Scholar, 11Fadok V.A. Xue D. Henson P. Cell Death Differ. 2001; 8: 582-587Crossref PubMed Scopus (80) Google Scholar, 12Fadok V.A Bratton D.L. Rose D.M. Pearson A. Ezekewitz R.A. Henson P.M. Nature. 2000; 405: 85-90Crossref PubMed Scopus (1247) Google Scholar). Recognition of surface PS by PSR initiates uptake of the apoptotic cells but does not induce inflammatory responses (12Fadok V.A Bratton D.L. Rose D.M. Pearson A. Ezekewitz R.A. Henson P.M. Nature. 2000; 405: 85-90Crossref PubMed Scopus (1247) Google Scholar, 13Henson P.M. Bratton D.L. Fadok V.A. Nat. Rev. Mol. Cell. Biol. 2001; 2: 627-633Crossref PubMed Scopus (288) Google Scholar). By specifically interacting with PS, PTP-MEG2 may have an important role in regulating cell-signaling pathways in this process.EXPERIMENTAL PROCEDURESMaterials—Commercial PIP strips spotted with 100 pmol of 16 different phospholipids were purchased from Echelon Research Lab (Salt Lake City, UT). Individual lipid compounds including phosphatidic acid, PC, PE, phosphatidylglycerol, phosphatidylinositol, PS, sphingomyelin, and cholesterol, all from natural sources, were purchased from Avanti Polar Lipids. Aranchidonic acid, oleic acid, linoleic acid, all-trans-retinal, and α-tocopherol were from Sigma. A mixture of retinal isomers was made by photoisomerization of all-trans-retinal as previously described (14Qi Y. Zhao R. Cao H. Sui X. Krantz S.B. Zhao Z.J. J. Cell. Biochem. 2002; 86: 79-89Crossref PubMed Scopus (20) Google Scholar). Homemade lipid strips were prepared by spotting on nitrocellulose membranes 1 μl of individual lipid compounds dissolved in chloroform/methanol (1:1 v/v) at a concentration of 0.01–1 mg/ml. The strips were air-dried and kept at 4 °C in the dark. Anti-PTP-MEG2 antibodies 144 and 159 were raised against peptides corresponding to amino acids 575–593 at the C terminus and to amino acids 297–314 in the middle of enzyme, respectively.Expression and Purification of Full-length and Truncated Forms of PTP-MEG2—Three recombinant PTP-MEG2 proteins were employed in this study (see Fig. 1). They are full-length form PTP-MEG2 (amino acid residues 1–593), N-terminal Sec14 domain-truncated form ΔNPTP-MEG2 (amino acid residues 283–593), and C-terminal catalytic domain-truncated form ΔCPTP-MEG2 (amino acid residues 1–329). PTP-MEG2 and ΔNPTP-MEG2 were purified by using adenovirus and Escherichia coli expression systems, respectively, as previously described (14Qi Y. Zhao R. Cao H. Sui X. Krantz S.B. Zhao Z.J. J. Cell. Biochem. 2002; 86: 79-89Crossref PubMed Scopus (20) Google Scholar). ΔCPTP-MEG2 was also expressed in the adenovirus. It contains a His6 tag at the C terminus without addition of any other extra amino acid residues. To generate the recombinant adenovirus carrying ΔCPTP-MEG2, a cDNA fragment encoding amino acids 1–329 of PTP-MEG2 plus a DNA sequence encoding 6 consecutive histidine residues was inserted into adenovirus transfer vector pACCMV.pLpA. Recombinant adenovirus was generated by co-transfection of 293 cells with the pACCMV.pLpA construct and pJM17 adenovirus genome DNA by using FuGENE 6 cell transfection reagent (Roche Applied Science). The resulting recombinant virus was purified by soft agar plaque assays and then amplified in 293 cells according to standard procedures (15Becker T.C. Noel R.J. Coats W.S. Gomez-Foix A.M. Alam T. Gerard R.D. Newgard C.B. Methods Cell Biol. 1994; 43: 161-189Crossref PubMed Scopus (561) Google Scholar). Positive clones were selected based on expression of ΔCPTP-MEG2 in infected 293 cells as determined by anti-PTP-MEG2 antibody 159. The purified recombinant adenovirus was used to infect 293 cells to express ΔCPTP-MEG2 following the protocol used for expression of the full-length PTP-MEG2 (14Qi Y. Zhao R. Cao H. Sui X. Krantz S.B. Zhao Z.J. J. Cell. Biochem. 2002; 86: 79-89Crossref PubMed Scopus (20) Google Scholar). The His6-tagged recombinant protein was purified from the cytosolic extracts of the infected cells by using a nickel-nitrilotriacetic acid column (Qiagen) following the manufacturer's protocol. The purity of the enzyme was about 90% as judged by Coomassie Blue staining. Western blotting analyses with antibody 159 showed single band of expected size (∼45 kDa).Lipid-membrane Overlay Assays—Nitrocellulose membrane strips spotted with various lipid compounds were incubated with 0.5 μg/ml full-length or truncated forms of PTP-MEG2 in Buffer A containing 10 mm Tris-HCl (pH 8.0), 0.15 m NaCl, 0.1% Tween 20, and 3% fatty acid-free bovine serum albumin (BSA). After extensive washing with Buffer A, enzymes bound to the membrane strips were probed with appropriate anti-PTP-MEG2 antibodies and then with horseradish peroxidase-conjugated anti-rabbit secondary antibodies. Detection was made by enhanced chemiluminescence reactions followed by exposure to x-ray film. The control experiments were performed without addition of any enzymes under the same conditions.Liposome Binding and Phosphatase Activity Assays—For liposome preparation, lipid mixtures in chloroform containing 320 μg PC and 80 μg PE plus 100 μg of indicated lipids were dried by using a speed vacuum concentrator and then were sonicated with a water bath sonicator in 0.5 ml of Buffer B containing 25 mm HEPES-NaOH (pH 7.0), 1 mm dithiothreitol, 0.15 m NaCl. The suspensions were centrifuged for 15 min at 14,000 rpm in a microcentrifuge. The pellets were resuspended by in 0.5 ml of Buffer B supplemented with 0.5 mg/ml BSA. For binding assays, 50 μl of the lipid vesicles were mixed with 2 μg of PTP-MEG2, ΔNPTP-MEG2, and ΔCPTP-MEG2 made in 20 μl of Buffer B plus 0.5 mg/ml BSA. After 15 min of incubation at room temperature, the samples were centrifuged at 14,000 rpm in a microcentrifuge, and both pellets and supernatants were used to make SDS gel samples. Equal proportions of the supernatants and pellets were subjected to Western blotting analyses with appropriate anti-PTP-MEG2 antibodies. For phosphatase activity assays, 2 mm para-nitrophenyl phosphate (pNPP) was added to the mixture of PTP-MEG2 and lipid vesicles before centrifugation. The reactions were allowed to proceed at room temperature for 20 min and were stopped by addition of 800 μl 0.2 m NaOH. Absorbance at 410 nm was measured and contributions by the lipid vesicles (∼10–20%) were subtracted in calculating the phosphatase activity.Transient Expression of Full-length and Truncated Forms of PTP-MEG2 in HT-1080 Cells and Immunofluorescent Cell Staining—HT-1080 fibrosarcoma cells seeded on glass cover slips were transfected with a pCDNA3 construct carrying N-terminal Sec14 domain-truncated ΔNPTP-MEG2 in the presence of the FuGENE 6 transfection reagent or infected with adenoviruses carrying full-length PTP-MEG2 or catalytic domain-truncated ΔCPTP-MEG2. After 48 h, the cells were fixed with 4% formaldehyde, permeabilized with 0.2% Triton X-100, and incubated with anti-PTP-MEG2 antibodies 144 or 159 and then with a Cy3-conjugated anti-rabbit secondary antibody. Cover slips were mounted onto glass slides and visualized by using a Zeiss Axiophot microscope with a 100× oil-immersion objective. Cell images were captured with a cooled CCD digital camera.Loading of PS into Cell Membranes—To verify the interaction of PS with PTP-MEG2 in intact cells, we followed a well established protocol to load excess amounts of PS into cell membranes (16Fadok V.A. Voelker D.R. Campbell P.A. Cohen J.J. Bratton D.L. Henson P.M. J. Immunol. 1992; 148: 2207-2216PubMed Google Scholar). For this purpose, unilayer lipid vesicles in phosphate-buffered saline containing 5 mg/ml PC (for controls) or a mixture of 2.5 mg/ml PC and 2.5 mg/ml PS, were prepared by sonication with a water bath sonicator as described above. The lipid vesicles were then added to PTP-MEG2 adenovirus-infected HT-1080 cells deprived of culture medium. Following 1 h of incubation at 37 °C, free lipid vesicles were removed by washing the cells with serum-containing medium. The cells then were incubated in normal tissue culture medium at 37 °C for 2 h to allow translocation of loaded PS from the outer leaflet to the inner leaflet by the aminophospholipid translocase. To detect the localization of PTP-MEG2, cells were fixed directly onto the tissue culture plates with 4% formaldehyde and stained with anti-PTP-MEG2 antibody 144 followed by probing with a Cy3-conjugated anti-rabbit secondary antibodies as described above. Fluorescent cell images were visualized by using an inverted microscope with a 40× objective (Nikon) and captured with a cooled CCD digital camera.RESULTSPTP-MEG2 Specifically Interacts with PS—To study the binding of PTP-MEG2 with known lipids, we employed a lipid-membrane overlay assay that has become a very popular method to analyze lipid-protein interactions in recent years (17Kanai F. Liu H. Field S.J. Akbary H. Matsuo T. Brown G.E. Cantley L.C. Yaffe M.B. Nat. Cell Biol. 2001; 3: 675-678Crossref PubMed Scopus (494) Google Scholar, 18Song X. Xu W. Zhang A. Huang G. Liang X. Virbasius J.V. Czech M.P. Zhou G.W. Biochemistry. 2001; 40: 8940-8944Crossref PubMed Scopus (106) Google Scholar, 19Snyder J.T. Rossman K.L. Baumeister M.A. Pruitt W.M. Siderovski D.P. Der C.J. Lemmon M.A. Sondek J. J. Biol. Chem. 2001; 276: 45868-45875Abstract Full Text Full Text PDF PubMed Scopus (80) Google Scholar, 20Varnai P. Lin X. Lee S.B. Tuymetova G. Bondeva T. Spat A. Rhee S.G. Hajnoczky G. Balla T. J. Biol. Chem. 2002; 277: 27412-27422Abstract Full Text Full Text PDF PubMed Scopus (105) Google Scholar, 21Zhan Y. Virbasius J.V. Song X. Pomerleau D.P. Zhou G.W. J. Biol. Chem. 2002; 277: 4512-4518Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar). We started with the PIP strips purchased from Echelon Research Lab. The strips were spotted with 100 pmol of 16 different phospholipids. Following the protocol recommended by the manufacturer, we probed the membrane with purified PTP-MEG2 at a final concentration of 0.5 μg/ml. As shown in Fig. 2, A and B, among the 16 phospholipids analyzed, PTP-MEG2 bound specifically to PS. In control experiments without PTP-MEG2, no signal was seen with PS despite a few weak and nonspecific signals seen with several other lipids. We further verified the results by using homemade phospholipid strips. In addition to some common phospolipids, we also included fatty acids, cholesterol, α-tocopherol, and retinal isomers. The data shown in Fig. 2C further confirmed the specific interaction of PTP-MEG2 with PS and ruled out binding with other lipid molecules tested. Further experiments as illustrated in Fig. 2D revealed that PTP-MEG2 could easily detect 25 ng of PS on the membrane.Fig. 2PTP-MEG2 specifically binds PS as revealed by lipid-membrane overlay assays. Phospholipid strips containing the indicated phospholipids were probed with 0.5 μg/ml PTP-MEG2 in a washing buffer containing 10 mm Tris-HCl (pH 8.0), 0.15 m NaCl, 0.1% Tween 20, and 3% fatty acid-free BSA. Bound proteins were detected by immunoblotting with anti-PTP-MEG2 antibody 144 and an horseradish peroxidase-conjugated anti-rabbit secondary antibody. Control experiments were performed following the same procedure except that PTP-MEG2 was omitted. Panels A and B, phospholipid strips spotted with 100 pmol of 16 different phospholipids purchased from Echelon Research Lab. Panels C and D, homemade lipid strips with indicated amounts of PS and 1 μg of all the other lipids. Additional abbreviations used: PA, phosphatidic acid; PG, phosphatidylglycerol; Sph, sphingomyelin; PI, phosphatidylinositol; PI3P, phosphatidylinositol 3-phosphate; PI4P, phosphatidylinositol 4-phosphate; PI5P, phosphatidylinositol 5-phosphate; PI3,4P2, phosphatidylinositol 3,4-bisphosphate; PI3,5P2, phosphatidylinositol 3,5-bisphosphate; PI4,5P2, phosphatidylinositol 4,5-bisphosphate; PI3,4,5P2, phosphatidylinositol 3,4,5-trisphosphate; AA, arachidonic acid. The letters p and a in the parentheses after the names of some phospho-inositides denote that the lipids from plant and animal, respectively.View Large Image Figure ViewerDownload (PPT)The Sec14 Domain Is Responsible for the Interaction of PTP-MEG2 with PS—The Sec14 domain of PTP-MEG2 is presumably involved in the interaction of PTP-MEG2 with PS. To verify this, we analyzed the binding of catalytic domain-truncated and Sec14 domain-truncated enzymes. ΔNPTP-MEG2 was purified from E. coli cells as previously described (14Qi Y. Zhao R. Cao H. Sui X. Krantz S.B. Zhao Z.J. J. Cell. Biochem. 2002; 86: 79-89Crossref PubMed Scopus (20) Google Scholar). However, ΔCPTP-MEG2 was largely insoluble when expressed in E. coli cells. We thus employed the adenovirus system for expression of the Sec14 domain as described for the full-length PTP-MEG2. The protein was expressed as a His6-tagged fusion protein. Over 70% of ΔCPTP-MEG2 was partitioned in the cytosolic extracts of recombinant adenovirus-infected 293 cells. By using a single nickel-nitrilotriacetic acid agarose column, we were able to enrich the recombinant protein from the cytosolic extracts to over 90% purity as revealed by Coomassie Blue staining, and Western blotting with anti-serum 159 showed a single protein band (Fig. 3). Fig. 4 shows the results of lipid membrane overlay assays obtained with the truncated enzymes. Although ΔCPTP-MEG2 displayed a specific binding to PS as observed with the full-length form of PTP-MEG2, ΔNPTP-MEG2 did not show any significant interaction with any of the lipids analyzed. These data indicate that the Sec14 domain mediates the interaction of PTP-MEG2 with PS.Fig. 3Purity of PTP-MEG2 and ΔCPTP-MEG2 revealed by SDS gels. Purified PTP-MEG2 and ΔCPTP-MEG2 as indicated were separated by 10% SDS gels and then stained with Coomassie Blue (left panels) or transferred to polyvinylidene difluoride membranes for Western blot analyses with PTP-MEG2 antiserum 159 (right panels).View Large Image Figure ViewerDownload (PPT)Fig. 4The Sec14 lipid-binding domain but not the PTP domain of PTP-MEG2 is responsible for binding with PS. Phospholipid strips from Echelon Research Lab were probed with 0.5 μg/ml ΔNPTP-MEG2 or ΔCPTP-MEG2 as described in the legend to Fig. 2 for the full-length PTP-MEG2. See Fig. 2 for abbreviations.View Large Image Figure ViewerDownload (PPT)PS-containing Liposomes Bind PTP-MEG2 but Do Not Affect its Enzymatic Activity toward pNPP—The interaction of PS with PTP-MEG2 was also confirmed by performing liposome-binding assays (22Gaullier J.-M. Simonsen A. D'Arrigo A. Bremnes B. Stenmark H. Nature. 1998; 394: 432-433Crossref PubMed Scopus (440) Google Scholar, 23Patki V. Lawe D.C. Corvera S. Virbasius J.V. Chawla A. Nature. 1998; 394: 433-434Crossref PubMed Scopus (249) Google Scholar). We used PC and PE as carriers for the lipids to be analyzed, and lipid vesicles were formed by sonication. For the recombinant PTP-MEG2 proteins, we employed BSA as a carrier, which is necessary to reduce the nonspecific binding of proteins to lipid vesicles. Upon incubation of the full-length and two truncated forms of PTP-MEG2 with the lipid vesicles followed by centrifugation, proteins bound to the lipid vesicles were recovered from the pellets. As shown in Fig. 5A, among the 8 phospholipids analyzed, only PS displayed a specific and strong binding to PTP-MEG2 as indicated by a near total recovery of the enzyme in the lipid vesicle pellet and a near depletion of the enzyme from the supernatant. All the other lipids showed marginal basal binding. As expected, a similar binding with PS was seen with ΔCPTP-MEG2 but not with ΔNPTP-MEG2. These data confirm not only the specific interaction of PTP-MEG2 with PS but also reveal the role of its Sec14 domain in the interaction. We further analyzed the effect of PS on the activity of PT-MEG2 with pNPP as a substrate (Fig. 5B), but we did not find any significant effect of the lipid on the catalytic activity of PTP-MEG2. If anything, it caused a slight inhibition, which was also seen with ΔNPTP-MEG2, which carries only the catalytic domain. Therefore, PS does not affect the activity of PTP-MEG2 at least toward pNPP. These results agree with our previous study in which the assays were performed with lipid micelle containing Triton X-100 (14Qi Y. Zhao R. Cao H. Sui X. Krantz S.B. Zhao Z.J. J. Cell. Biochem. 2002; 86: 79-89Crossref PubMed Scopus (20) Google Scholar). However, these data do not rule out the possible effects on PTP-MEG2 activity toward physiological substrates. By using the same procedures, we have analyzed binding and regulatory ability of other lipid molecules as described in Fig. 2. None of them showed any significant binding or regulatory activity (data not shown).Fig. 5PTP-MEG2 specifically binds liposomes containing PS, but its catalytic activity toward pNPP was not significantly affected. A, liposomes containing PC, PE, and one of the indicated lipids were incubated with PTP-MEG2, ΔNPTP-MEG2, or ΔCPTP-MEG2. Liposome-bound and -free enzymes were separated by centrifugation. Equal proportions of samples were subjected to Western blotting analyses with anti-PTP-MEG2 antibody 144 (for PTP-MEG2 and ΔNPTP-MEG2) and 159 (for ΔCPTP-MEG2). See “Experimental Procedures” for detail. B, analysis of the catalytic activity of PTP-MEG2 and ΔNPTP-MEG2 in the presence of liposomes containing PS. Data represent relative activity.View Large Image Figure ViewerDownload (PPT)The Sec14 Domain Is Responsible for the Localization of PTP-MEG2 to the Perinuclear Region—We performed immunofluoresecent cell staining to determine the intracellular localization of PTP-MEG2 as shown in Fig. 6. Staining of wild type HT-1080 cells with antibody 144 revealed a moderate expression of endogenous PTP-MEG2 in the perinuclear region resembling the endoplasmic reticulum and Golgi apparatus. This localization is further confirmed by a much more intensive staining of over-expressed PTP-MEG2 in the same region upon infection of the cells with recombinant adenovirus carrying the full-length form of PTP-MEG2. Furthermore, ΔCPTP-MEG2 that contains the Sec14 domain alone displayed exactly the same staining pattern as seen with full-length PTP-MEG2. In contrast, truncation of the Sce14 domain resulted in the distribution of ΔNPTP-MEG2 in the entire cytoplasma. Note that ΔNPTP-MEG2 corresponds to the catalytic domain of PTP-MEG2. These data indicate that the N-terminal Sec14 domain of PTP-MEG2 is necessary and sufficient for the perinuclear localization of the enzyme. We believe that PS present in the perinuclear region may be responsible for such localization.Fig. 6The Sec14 domain is responsible for localization of PTP-MEG2 to the perinuclear region. HT-1080 cells grown on glass cover slips were left untreated, infected with adenoviruses carrying full-length PTP-MEG2 and catalytic domain-truncated ΔCPTP-MEG2, or transfected with Sec14 domain-truncated ΔNPTP-MEG2 constructed into the pCDNA3 vector. After 24 h, cells were fixed for staining with antibodies 144 or 159 as indicated. Note that exposure time for the wild type cells was substantially longer.View Large Image Figure ViewerDownload (PPT)Loading of PS into the Cell Membrane Alters Localization of PTP-MEG2—Translocation is one of the major mechanisms by which an enzyme or protein is regulated. Although PS does not change the catalytic activity of PTP-MEG2 (toward pNPP at least), it may regulate the enzyme by controlling its intracellular localization. To study the effects of PS on the localization, cells were loaded with lipid vesicles containing 50% PS and 50% PC according to a published protocol (16Fadok V.A. Voelker D.R. Campbell P.A. Cohen J.J. Bratton D.L. Henson P.M. J. Immunol. 1992; 148: 2207-2216PubMed Google Scholar). Lipid vesicles made of 100% PC were used as control. The data are shown in Fig. 7. In non-treated cells and cells treated with control PC lipid vesicles, PTP-MEG2 was localized exclusively in the perinuclear region. However, loading of cells with PS caused partial localization of PTP-MEG2 to the plasma membrane. This translocation of PTP-MEG2 to the plasma membrane depended on incubation time after treatment with PS. Plasma membrane localization was apparent 2 h after PS treatment but totally disappeared 8 h later. This presumably reflects the redistribution of PS in the cells. Together, the data demonstrate a binding of PTP-MEG2 with PS in intact cells and an important role for PS in controlling localization of PTP-MEG2. It should be pointed out that the intracellular balance of PS may be the determinant factor for the localization of PTP-MEG2. Under normal conditions, PTP-MEG2 may be retained in perinuclear region by PS there, and the amount of PS present in the inner layer of the plasma membrane is apparently not sufficient to cause a translocation of the enzyme. We believe that a perturbation of PS distribution associated with cellular processes should target PTP-MEG2 to specific membrane compartments.Fig. 7Loading of PS into cell membranes alters localization of PTP-MEG2. HT-1080 cells plated in cell culture plates were infected with recombinant PTP-MEG2 adenovirus and cultured overnight to give rise to 50–80% PTP-MEG2-expressing cells. Cells were then treated with PC or PC/PS for 1 h as described in “Experimental Procedures.” Following treatment, cells were further cultured in normal culture medium for 2 or 8 h as indicated before staining with anti-PTP-MEG2 antibody 144. Arrows indicate plasma membrane localization of PTP-MEG2.View Large Image Figure ViewerDownload (PPT)DISCUSSIONIt has been well accepted that phospholipids are not only components of cell membranes but also act as important second messengers (24Vanhaesebroeck B. Leevers S.J. Ahmadi K. Timms J. Katso R. Driscoll P.C. Woscholski R. Parker P.J. Waterfield M.D. Annu. Rev. Biochem. 2001; 70: 535-602Crossref PubMed Scopus (1357) Google Scholar). A major characteristic of lipid second messengers is that they cannot diffuse freely through the aqueous compartments of cells. Once produced in a particular cell membrane, they stay there and often serve as markers for the membrane compartment until they are enzymatically converted or translocated or the membrane buds off or fuses with another. This membrane confinement makes lipid messengers ideal regulators of subcellular localization. Many proteins are localized to specific cellular compartments through conserved domains that specifically recognize particular membrane-bound lipids. PH, FYVE, and PX domains are some examples that have attracted much attention in recent years (17Kanai F. Liu H. Field S.J. Akbary H. Matsuo T. Brown G.E. Cantley L.C. Yaffe M.B. Nat. Cell Biol. 2001; 3: 675-678Crossref PubMed Scopus (494) Google Scholar, 18Song X. Xu W. Zhang A. Huang G. Liang X. Virbasius J.V. Czech M.P. Zhou G.W. Biochemistry. 2001; 40: 8940-8944Crossref PubMed Scopus (106) Google Scholar, 19Snyder J.T. Rossman K.L. Baumeister M.A. Pruitt W.M. Siderovski D.P. Der C.J. Lemmon M.A. Sondek J. J. Biol. Chem. 2001; 276: 45868-45875Abstract Full Text Full Text PDF PubMed Scopus (80) Google Scholar, 20Varnai P. Lin X. Lee S.B. Tuymetova G. Bondeva T. Spat A. Rhee S.G. Hajnoczky G. Balla T. J. Biol. Chem. 2002; 277: 27412-27422Abstract Full Text Full Text PDF PubMed Scopus (105) Google Scholar, 21Zhan Y. Virbasius J.V. Song X. Pomerleau D.P. Zhou G.W. J. Biol. Chem. 2002; 277: 4512-4518Abstract Full Text Full Text PDF PubMed Scopus (98) Google Scholar, 22Gaullier J.-M. Simonsen A. D'Arrigo A. Bremnes B. Stenmark H. Nature. 1998; 394: 432-433Crossref PubMed Scopus (440) Google Scholar, 23Patki V. Lawe D.C. Corvera S. Virbasius J.V. Chawla A. Nature. 1998; 394: 433-434Crossref PubMed Scopus (249) Google Scholar, 24Vanhaesebroeck B. Leevers S.J. Ahmadi K." @default.
• W2080285165 created "2016-06-24" @default.
• W2080285165 creator A5010933629 @default.
• W2080285165 creator A5054433231 @default.
• W2080285165 creator A5062050451 @default.
• W2080285165 creator A5063208606 @default.
• W2080285165 creator A5088086755 @default.
• W2080285165 date "2003-06-01" @default.
• W2080285165 modified "2023-10-16" @default.
• W2080285165 title "Specific Interaction of Protein Tyrosine Phosphatase-MEG2 with Phosphatidylserine" @default.
• W2080285165 cites W1482207773 @default.
• W2080285165 cites W1499176799 @default.
• W2080285165 cites W1517631297 @default.
• W2080285165 cites W1532455251 @default.
• W2080285165 cites W1565831796 @default.
• W2080285165 cites W1574748879 @default.
• W2080285165 cites W185254773 @default.
• W2080285165 cites W1884848820 @default.
• W2080285165 cites W1966533220 @default.
• W2080285165 cites W1986709440 @default.
• W2080285165 cites W1989433761 @default.
• W2080285165 cites W1995088117 @default.
• W2080285165 cites W2000570698 @default.
• W2080285165 cites W2012514869 @default.
• W2080285165 cites W2021450034 @default.
• W2080285165 cites W2049144892 @default.
• W2080285165 cites W2058505728 @default.
• W2080285165 cites W2069109360 @default.
• W2080285165 cites W2070331057 @default.
• W2080285165 cites W2080435414 @default.
• W2080285165 cites W2085420819 @default.
• W2080285165 cites W2088363390 @default.
• W2080285165 cites W2088972036 @default.
• W2080285165 cites W2095537212 @default.
• W2080285165 cites W2097231556 @default.
• W2080285165 cites W2131523916 @default.
• W2080285165 cites W2134699117 @default.
• W2080285165 cites W2160421139 @default.
• W2080285165 cites W2164139183 @default.
• W2080285165 cites W2166753483 @default.
• W2080285165 cites W2315511855 @default.
• W2080285165 cites W4235300003 @default.
• W2080285165 cites W988054948 @default.
• W2080285165 doi "https://doi.org/10.1074/jbc.m301560200" @default.
• W2080285165 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12702726" @default.
• W2080285165 hasPublicationYear "2003" @default.
• W2080285165 type Work @default.
• W2080285165 sameAs 2080285165 @default.
• W2080285165 citedByCount "32" @default.
• W2080285165 countsByYear W20802851652012 @default.
• W2080285165 countsByYear W20802851652014 @default.
• W2080285165 countsByYear W20802851652015 @default.
• W2080285165 countsByYear W20802851652016 @default.
• W2080285165 countsByYear W20802851652017 @default.
• W2080285165 countsByYear W20802851652023 @default.
• W2080285165 crossrefType "journal-article" @default.
• W2080285165 hasAuthorship W2080285165A5010933629 @default.
• W2080285165 hasAuthorship W2080285165A5054433231 @default.
• W2080285165 hasAuthorship W2080285165A5062050451 @default.
• W2080285165 hasAuthorship W2080285165A5063208606 @default.
• W2080285165 hasAuthorship W2080285165A5088086755 @default.
• W2080285165 hasBestOaLocation W20802851651 @default.
• W2080285165 hasConcept C11960822 @default.
• W2080285165 hasConcept C178666793 @default.
• W2080285165 hasConcept C185592680 @default.
• W2080285165 hasConcept C2776165026 @default.
• W2080285165 hasConcept C2778918659 @default.
• W2080285165 hasConcept C2779637612 @default.
• W2080285165 hasConcept C41625074 @default.
• W2080285165 hasConcept C55493867 @default.
• W2080285165 hasConcept C85528070 @default.
• W2080285165 hasConceptScore W2080285165C11960822 @default.
• W2080285165 hasConceptScore W2080285165C178666793 @default.
• W2080285165 hasConceptScore W2080285165C185592680 @default.
• W2080285165 hasConceptScore W2080285165C2776165026 @default.
• W2080285165 hasConceptScore W2080285165C2778918659 @default.
• W2080285165 hasConceptScore W2080285165C2779637612 @default.
• W2080285165 hasConceptScore W2080285165C41625074 @default.
• W2080285165 hasConceptScore W2080285165C55493867 @default.
• W2080285165 hasConceptScore W2080285165C85528070 @default.
• W2080285165 hasIssue "25" @default.
• W2080285165 hasLocation W20802851651 @default.
• W2080285165 hasOpenAccess W2080285165 @default.
• W2080285165 hasPrimaryLocation W20802851651 @default.
• W2080285165 hasRelatedWork W1968905431 @default.
• W2080285165 hasRelatedWork W1999863139 @default.
• W2080285165 hasRelatedWork W2043949158 @default.
• W2080285165 hasRelatedWork W2047780246 @default.
• W2080285165 hasRelatedWork W2095293337 @default.
• W2080285165 hasRelatedWork W2767471468 @default.
• W2080285165 hasRelatedWork W4223460875 @default.
• W2080285165 hasRelatedWork W4225369895 @default.
• W2080285165 hasRelatedWork W4307340632 @default.
• W2080285165 hasRelatedWork W4317831504 @default.
• W2080285165 hasVolume "278" @default.
• W2080285165 isParatext "false" @default.
• W2080285165 isRetracted "false" @default.
• W2080285165 magId "2080285165" @default.

• next